The text starts here.

News Release

FOR IMMEDIATE RELEASE
February 25th, 2005

US FDA Tentative Approval for ANDA Filing of Donepezil Hydrochloride

Eisai Co., Ltd.
Eisai Inc.

U.S. Food & Drug Administration (FDA) announced on their website that FDA has issued a tentative approval for donepezil hydrochloride to Ranbaxy Laboratories Ltd. Donepezil is Eisai's branded medicine Aricept(R) .

The tentative approval by FDA does not authorize Ranbaxy Laboratories Ltd. to sell and market donepezil hydrochloride before the expiry of the Eisai's product patent. Eisai s donepezil will be protected at least until its product patent expiry in November 2010. The tentative approval will not be effective before November 2010.



Contact:
Corporate Communications DepartmentCathy Pollini
Eisai Co., Ltd. Corporate Public Relations
81-3-3817-5120Eisai Inc.
1-201-287-2052